Baseline information on selected gliomas by Hsp27, p-Hsp27, IDH1 mutation and ATRX loss
| Variable | No. | Hsp27 | High p-Hsp27 | IDH1 mutation | ATRX loss |
| Gender | |||||
| Male | 240 | 45 (18.8%) | 42 (17.5%) | 75 (31.3%) | 47 (19.6%) |
| Female | 181 | 46 (25.4%) | 41 (22.7%) | 48 (26.5%) | 36 (19.9%) |
| P value | 0.100 | 0.188 | 0.291 | 0.938 | |
| Age (years) | |||||
| ≤50 | 225 | 40 (17.8%) | 34 (15.1%) | 92 (40.9%) | 66 (29.3%) |
| >50 | 196 | 51 (26.0%) | 49 (25.0%) | 31 (15.8%) | 17 (8.7%) |
| P value | 0.040 | 0.011 | <0.001 | <0.001 | |
| KPS | |||||
| ≤60 | 87 | 20 (23.0%) | 17 (19.5%) | 25 (28.7%) | 14 (16.1%) |
| >60 | 215 | 46 (21.4%) | 46 (21.4%) | 62 (28.8%) | 49 (22.8%) |
| NA | 119 | 25 (21.0%) | 20 (16.8%) | 36 (30.3%) | 20 (16.8%) |
| P value | 0.938 | 0.600 | 0.958 | 0.267 | |
| Grade | |||||
| 2 | 77 | 8 (10.4%) | 2 (2.6%) | 32 (41.6%) | 24 (31.2%) |
| 3 | 65 | 13 (20.0%) | 15 (23.1%) | 27 (41.5%) | 16 (24.6%) |
| 4 | 279 | 70 (25.1%) | 66 (23.7%) | 64 (22.9%) | 43 (15.4%) |
| P value | 0.012 | <0.001 | <0.001 | 0.005 | |
| Pathology | |||||
| A | 52 | 6 (11.5%) | 1 (2.0%) | 17 (32.7%) | 19 (36.5%) |
| O | 16 | 2 (12.5%) | 1 (6.3%) | 8 (50.0%) | 2 (12.5%) |
| OA | 9 | 0 (0.0%) | 0 (0.0%) | 7 (77.8%) | 3 (33.3%) |
| AA | 39 | 11 (28.2%) | 12 (30.8%) | 11 (28.2%) | 11 (28.2%) |
| AO | 15 | 1 (6.7%) | 1 (6.7%) | 10 (66.7%) | 1 (6.7%) |
| AOA | 11 | 1 (9.9%) | 2 (18.2%) | 6 (54.5%) | 4 (36.4%) |
| pGBM | 233 | 67 (28.8%) | 63 (27.0%) | 32 (13.7%) | 28 (12.0%) |
| sGBM | 46 | 3 (6.5%) | 3 (6.5%) | 32 (69.6%) | 15 (32.6%) |
| P value | <0.001 | <0.001 | <0.001 | <0.001 | |
A, astrocytoma; AA, anaplastic astrocytoma; AO, anaplastic oligodendroglioma; AOA, anaplastic oligoastrocytoma; KPS, Karnofsky Performance Status; O, oligodendroglioma; OA, oligoastrocytoma; pGBM, primary glioblastoma; sGBM, secondary glioblastoma.